公开(公告)号：EP3057965A4

公开(公告)日：2017-05-24

申请号：EP14854037

申请日：2014-10-17

Applicant: UNIV HEALTH NETWORK

Inventor： SAMPSON PETER BRENT ,  FEHER MIKLOS ,  PAULS HEINZ W

IPC: C07D413/14 ,  A61K31/5377 ,  A61P35/00

CPC classification number: C07D413/14

Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer. Compound (I)

Abstract translation: 公开了由以下结构式表示的化合物（I）的富马酸盐和马来酸盐及其相应的药物组合物。 1：1化合物（I）延胡索酸盐和1：1化合物（I）马来酸盐的特定单晶形式的特征在于各种性质和物理测量。 还公开了制备1：1化合物（I）富马酸盐和1：1化合物（I）马来酸盐的特定结晶形式的方法。 本发明还提供了治疗患有癌症的受试者的方法。 化合物（I）

公开(公告)号：EP3068786A4

公开(公告)日：2017-04-12

申请号：EP14861448

申请日：2014-11-14

Applicant: UNIV HEALTH NETWORK

Inventor： LAUFER RADOSLAW ,  NG GRACE ,  LI SZE-WAN ,  PAULS HEINZ W ,  LIU YONG ,  PATEL NARENDRA KUMAR B

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00

CPC classification number: C07D487/04 ,  C07D519/00

Abstract: The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

Abstract translation: 本教导提供由结构式（1-0）表示的化合物或其药学上可接受的盐。 还描述了药物组合物及其使用方法。

公开(公告)号：EP2556070A4

公开(公告)日：2013-10-23

申请号：EP11764989

申请日：2011-04-06

Applicant: UNIV HEALTH NETWORK

Inventor： CUMMING GRAHAM ,  PATEL NARENDA KUMAR B ,  FORREST BRYAN T ,  LIU YONG ,  LI SZE-WAN ,  SAMPSON PETER BRENT ,  EDWARDS LOUISE G ,  PAULS HEINZ W

IPC: C07D413/14 ,  A61K31/5377 ,  A61P35/00 ,  C07D231/56 ,  C07D403/04 ,  C07D403/10 ,  C07D403/14

CPC classification number: C07D403/10 ,  A61K31/5377 ,  A61K45/06 ,  C07D231/56 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14

Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

公开(公告)号：MX385289B

公开(公告)日：2025-03-18

申请号：MX2019000744

申请日：2019-01-17

Applicant: UNIV HEALTH NETWORK

Inventor： PAULS HEINZ W ,  SAMPSON PETER BRENT ,  LI SZE- WAN

IPC: A61K31/519 ,  A61P35/00 ,  C07D487/04 ,  C30B7/02

Abstract: La presente invencion se refiere a un novedoso co-cristal del compuesto de formula (I): (Formula (I)) en donde la molecula co-formadora es hemihidrato de bifosfato, a procesos para la preparacion del co-cristal, a composiciones farmaceuticas que contienen el co-cristal, al uso de tal co-cristal en la manufactura de un medicamento para uso en el tratamiento de cancer y a métodos para tratar tales enfermedades en el cuerpo humano o animal por administracion de una cantidad terapeuticamente efectiva de tal co-cristal.

公开(公告)号：AU2021221447A1

公开(公告)日：2021-10-07

申请号：AU2021221447

申请日：2021-08-24

Applicant: UNIV HEALTH NETWORK

Inventor： LI SZE-WAN ,  PAULS HEINZ W ,  SAMPSON PETER BRENT

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00 ,  C30B7/02

Abstract: Abstract The present invention relates to a hydrobromide salt of the compound of formula (1), to process for the preparation of the hydrobromide salt, to pharmaceutical compositions containing the hydrobromide salt, to the use of such a hydrobromide salt in the manufacture of a medicament for use in the treatment of cancer and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of such a hydrobromide salt. H $ NH 0 H (I)

公开(公告)号：MD3322711T2

公开(公告)日：2021-07-31

申请号：MDE20180529

申请日：2016-06-23

Applicant: UNIV HEALTH NETWORK

Inventor： SAMPSON PETER BRENT ,  PATEL NARENDRA KUMAR B ,  PAULS HEINZ W ,  LI SZE-WAN ,  NG GRACE ,  LAUFER RADOSLAW ,  LIU YONG ,  LANG YUNHUI

IPC: C07D495/04 ,  A61K31/4355 ,  A61K31/4436 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/551 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

Abstract: Sunt descrişi compuşii tienopiridinonici cu Formula (I) şi sărurile acceptabile farmaceutic ale acestora. În aceşti compuşi, unul dintre X1; X2 şi X3 sunt S şi celelalte două sunt fiecare independent CR, în care R şi toate celelalte variabile sunt definite aici. Se arată că compuşii inhibă activitatea kinazei HPK1 şi au activitate antitumorală in vivo. Compuşii pot fi combinaţi eficient cu purtători acceptabili farmaceutic şi, de asemenea, cu alte abordări imunomodulatoare, cum ar fi inhibarea punctului de control sau inhibitorii oxidării triptofanului. Formula (I).

公开(公告)号：NZ718744A

公开(公告)日：2021-07-30

申请号：NZ71874414

申请日：2014-10-17

Applicant: UNIV HEALTH NETWORK

Inventor： PAULS HEINZ W ,  SAMPSON PETER BRENT ,  FEHER MIKLOS

IPC: C07D413/14 ,  A61K31/5377 ,  A61P35/00

Abstract: Fumarate and maleate salts of compound (I), a PLK-4 inhibitor, are disclosed wherein the molar ratio is 1:1. These salts form crystalline solids which are suitable for pharmaceutical development and preparing pharmaceutical compositions. These fumarate and maleate crystalline forms have good oral bioavailability. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are disclosed along with the use of the fumarate and maleate salts of compound (I) for the treatment of cancers.

公开(公告)号：AU2016282289B2

公开(公告)日：2020-12-24

申请号：AU2016282289

申请日：2016-06-23

Applicant: UNIV HEALTH NETWORK

Inventor： SAMPSON PETER BRENT ,  PATEL NARENDRA KUMAR B ,  PAULS HEINZ W ,  LI SZE-WAN ,  NG GRACE ,  LAUFER RADOSLAW ,  LIU YONG ,  LANG YUNHUI

IPC: C07D495/04 ,  A61K31/4436 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/551 ,  A61K39/395 ,  A61P35/00

Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X

公开(公告)号：PL3057965T3

公开(公告)日：2019-08-30

申请号：PL14854037

申请日：2014-10-17

Applicant: UNIV HEALTH NETWORK

Inventor： SAMPSON PETER BRENT ,  FEHER MIKLOS ,  PAULS HEINZ W

IPC: C07D413/14 ,  A61K31/5377 ,  A61P35/00

公开(公告)号：AU2014336929B9

公开(公告)日：2019-03-21

申请号：AU2014336929

申请日：2014-10-17

Applicant: UNIV HEALTH NETWORK

Inventor： SAMPSON PETER BRENT ,  FEHER MIKLOS ,  PAULS HEINZ W

IPC: C07D413/14 ,  A61K31/5377 ,  A61P35/00

Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer. Compound (I)